A DNA vaccine that targets mbKitL is able to inhibit the growth of a mouse HER2 positive transplantable tumor; vaccination impairs tumor vessel formation and stabilization and thus interferes with tumor cell-derived VEGF bioavailability [97]. The gene discussed is ERBB2; the disease is neoplasm.